ESR1 and breast cancer: Although tamoxifen has been a great success and improves breast cancer survival rates considerably [4-6], a significant proportion of ERα-positive breast cancer is tamoxifen-unresponsive, and tamoxifen-resistant cases have been also reported [7,8].